Idiopathic multicentric Castleman disease: bringing order to chaos
Publication date: Available online 3 February 2020Source: The Lancet HaematologyAuthor(s): Heather A Leitch (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 5, 2020 Category: Hematology Source Type: research

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials
This study was done to assess the long-term safety and activity of siltuximab over up to 6 years of treatment.MethodsThis study is a prespecified open-label extension analysis of a phase 1 trial (NCT00412321) and a phase 2 trial (NCT01024036), done at 26 hospitals worldwide. Patients in both studies were at least 18 years old with histologically confirmed, symptomatic Castleman disease. This extension study enrolled 60 patients who completed the previous trials without disease progression on siltuximab. Patients received siltuximab infusions of 11 mg/kg every 3 weeks (which could be extended to 6 weeks) for up to 6 years. ...
Source: The Lancet Haematology - February 5, 2020 Category: Hematology Source Type: research

Interferon-α: alternative first- or second-line therapeutic option for polycythaemia vera
Publication date: Available online 31 January 2020Source: The Lancet HaematologyAuthor(s): John Mascarenhas (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 1, 2020 Category: Hematology Source Type: research

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
We present the final results of PROUD-PV and an interim analysis at 36 months of the CONTINUATION-PV study (per statistical analysis plan). Analyses for safety and efficacy were per-protocol. The trials were registered on EudraCT, 2012-005259-18 (PROUD-PV) and 2014-001357-17 (CONTINUATION-PV, which is ongoing).FindingsPatients were recruited from Sept 17, 2013 to March 13, 2015 with 306 enrolled. 257 patients were randomly assigned, 127 were treated in each group (three patients withdrew consent in the hydroxyurea group), and 171 rolled over to the CONTINUATION-PV trial. Median follow-up was 182·1 weeks (IQR 166&mid...
Source: The Lancet Haematology - February 1, 2020 Category: Hematology Source Type: research

Correction to Lancet Haematol 2020; 7: e100–11
Publication date: Available online 29 January 2020Source: The Lancet HaematologyAuthor(s): (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 30, 2020 Category: Hematology Source Type: research

Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
Publication date: February 2020Source: The Lancet Haematology, Volume 7, Issue 2Author(s): Olaf Penack, Monia Marchetti, Tapani Ruutu, Mahmoud Aljurf, Andrea Bacigalupo, Francesca Bonifazi, Fabio Ciceri, Jan Cornelissen, Ram Malladi, Rafael F Duarte, Sebastian Giebel, Hildegard Greinix, Ernst Holler, Anita Lawitschka, Stephan Mielke, Mohamad Mohty, Mutlu Arat, Arnon Nagler, Jakob Passweg, Hélène SchoemansSummaryGraft-versus-host disease (GVHD) is a major factor contributing to mortality and morbidity after allogeneic stem-cell transplantation. Because of the small number of results from well designed, large-s...
Source: The Lancet Haematology - January 30, 2020 Category: Hematology Source Type: research

Childhood cancer: the need to invest in the future
Publication date: February 2020Source: The Lancet Haematology, Volume 7, Issue 2Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 30, 2020 Category: Hematology Source Type: research

The demand and supply of blood in India
Publication date: February 2020Source: The Lancet Haematology, Volume 7, Issue 2Author(s): Joy John Mammen, Edwin Sam Asirvatham (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 30, 2020 Category: Hematology Source Type: research

Caution: PET-CT in plasma cell disorders
Publication date: February 2020Source: The Lancet Haematology, Volume 7, Issue 2Author(s): Deepesh P Lad (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 30, 2020 Category: Hematology Source Type: research

Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations
Publication date: February 2020Source: The Lancet Haematology, Volume 7, Issue 2Author(s): Francesco Paolo Tambaro, William G WierdaSummaryTumour lysis syndrome is a complication of chemotherapy for haematological malignancies; in particular, aggressive leukaemias and lymphomas. For haematological malignancies, targeted therapies, such as small molecule inhibitors and monoclonal antibodies, have a high anti-tumour activity, are well tolerated, and have a low incidence of associated tumour lysis syndrome. The BCL-2 inhibitor venetoclax has a high anti-tumour activity in chronic lymphocytic leukaemia, achieving deep remissio...
Source: The Lancet Haematology - January 30, 2020 Category: Hematology Source Type: research

Polycythaemia vera, ruxolitinib, and hydroxyurea: where do we go now?
Publication date: Available online 23 January 2020Source: The Lancet HaematologyAuthor(s): Jerry L Spivak (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 25, 2020 Category: Hematology Source Type: research

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
This study is registered with ClinicalTrials.gov, NCT01243944.FindingsWe enrolled patients between Oct 27, 2010, and Feb 13, 2013, and the study concluded on Feb 9, 2018. Of 342 individuals screened for eligibility, 222 patients were randomly assigned to receive ruxolitinib (n=110, 50%) or best available therapy (n=112, 50%). The median time since polycythaemia vera diagnosis was 8·2 years (IQR 3·9–12·3) in the ruxolitinib group and 9·3 years (4·9–13·8) in the best available therapy group. 98 (88%) of 112 patients initially randomly assigned to best available therapy cr...
Source: The Lancet Haematology - January 25, 2020 Category: Hematology Source Type: research

First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an “operational cure”
Publication date: Available online 21 January 2020Source: The Lancet HaematologyAuthor(s): Massimo Breccia, Robin Foà (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 22, 2020 Category: Hematology Source Type: research

Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial
This study closed early due to accrual and is registered with the UMIN Clinical Trials Registry (UMIN000011099).FindingsBetween Sept 20, 2013 and July 12, 2016, 68 patients who had a deep molecular response after receiving first-line dasatinib for at least 24 months were enrolled and assigned to the consolidation phase. Nine patients were excluded during the consolidation phase and one patient was excluded after study completion because of meeting exclusion criteria. 58 patients discontinued dasatinib and were assessed. 32 (55%) of 58 patients had treatment-free remission at 6 months after dasatinib discontinuation, and me...
Source: The Lancet Haematology - January 22, 2020 Category: Hematology Source Type: research

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial
Publication date: Available online 17 January 2020Source: The Lancet HaematologyAuthor(s): Irwin Walker, Tony Panzarella, Stephen Couban, Felix Couture, Gerald Devins, Mohamed Elemary, Geneviève Gallagher, Holly Kerr, John Kuruvilla, Stephanie J Lee, John Moore, Thomas Nevill, Gizelle Popradi, Jean Roy, Kirk R Schultz, David Szwajcer, Cynthia Toze, Ronan Foley, Cell Therapy Transplant CanadaSummaryBackgroundPrevious trials testing prevention strategies for chronic graft versus host disease (GVHD) have measured its cumulative incidence. In this trial of anti-thymocyte globulin, we measured treatment-independence at a...
Source: The Lancet Haematology - January 18, 2020 Category: Hematology Source Type: research

What's behind chronic graft versus host disease incidence curves?
Publication date: Available online 17 January 2020Source: The Lancet HaematologyAuthor(s): Alberto Mussetti, Anna Sureda (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 18, 2020 Category: Hematology Source Type: research

Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study
Publication date: Available online 13 January 2020Source: The Lancet HaematologyAuthor(s): Abi Vijenthira, Kelvin Chan, Matthew C Cheung, Anca PricaSummaryBackgroundSeveral strategies are available for the initial treatment of advanced-stage Hodgkin lymphoma, but the optimal strategy in terms of cost-effectiveness is unclear. The aim of this study was to compare the quality-adjusted effectiveness and costs of five modern treatment options for transplantation-eligible patients with newly diagnosed advanced-stage Hodgkin lymphoma.MethodsA Markov decision-analytic model was developed using a 20-year time horizon. Five of the ...
Source: The Lancet Haematology - January 15, 2020 Category: Hematology Source Type: research

Cost considerations in the first-line treatment of advanced Hodgkin lymphoma
Publication date: Available online 13 January 2020Source: The Lancet HaematologyAuthor(s): Anthony J Perissinotti (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 15, 2020 Category: Hematology Source Type: research

Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study
This study aimed to investigate the clinical features and outcomes of patients with myelodysplastic syndrome or acute myeloid leukaemia and Shwachman-Diamond syndrome, an inherited bone marrow failure disorder with high risk of developing myeloid malignancies.MethodsWe did a multicentre, retrospective, cohort study in collaboration with the North American Shwachman-Diamond Syndrome Registry. We reviewed patient medical records from 17 centres in the USA and Canada. Patients with a genetic (biallelic mutations in the SBDS gene) or clinical diagnosis (cytopenias and pancreatic dysfunction) of Shwachman-Diamond syndrome who d...
Source: The Lancet Haematology - December 24, 2019 Category: Hematology Source Type: research

Correction to Lancet Haematol 2019; 6: e398–408
Publication date: January 2020Source: The Lancet Haematology, Volume 7, Issue 1Author(s): (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 24, 2019 Category: Hematology Source Type: research

Correction to Lancet Haematol 2019; 6: e385–86
Publication date: January 2020Source: The Lancet Haematology, Volume 7, Issue 1Author(s): (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 24, 2019 Category: Hematology Source Type: research

Bruton tyrosine-kinase inhibitor on the rise: acalabrutinib in Waldenström macroglobulinemia
Publication date: Available online 19 December 2019Source: The Lancet HaematologyAuthor(s): Christian Buske (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 21, 2019 Category: Hematology Source Type: research

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
This study is registered with ClinicalTrials.gov, number NCT02180724, and is ongoing, but no longer enrolling.FindingsBetween Sept 8, 2014, and Dec 24, 2015, 122 patients were assessed for eligibility, of which 106 (87%) patients were given acalabrutinib (14 were treatment naive and 92 had relapsed or refractory disease). With a median follow-up of 27·4 months (IQR 26·0–29·7), 13 (93% [95% CI 66–100]) of 14 treatment naive patients achieved an overall response and 86 (93% [86–98]) of 92 relapsed or refractory patients per both the modified 3rd and 6th IWWM criteria. Seven (50%) of 14 ...
Source: The Lancet Haematology - December 21, 2019 Category: Hematology Source Type: research

2019 ASH Annual Meeting
Publication date: Available online 16 December 2019Source: The Lancet HaematologyAuthor(s): Farhat Yaqub (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 18, 2019 Category: Hematology Source Type: research

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial
This study is registered with Clinicaltrials.gov, number NCT02560025, and has completed enrolment.FindingsBetween Dec 31, 2015, and Aug 1, 2017, we enrolled a total of 39 eligible patients. 19 (49%) of 39 patients had secondary acute myeloid leukaemia and three (8%) had therapy-related acute myeloid leukaemia. At mid-induction, 33 (85%) of 39 patients showed marrow aplasia, six (15%) received re-induction. The median follow-up was 13·7 months (IQR 12·7–14·4). Composite remission was 64% (two-stage 95% CI 48–79), with 20 (51%) of 39 patients achieving complete remission and five (13%) achiev...
Source: The Lancet Haematology - December 12, 2019 Category: Hematology Source Type: research

Alisertib: a new option for acute myeloid leukaemia
Publication date: Available online 11 December 2019Source: The Lancet HaematologyAuthor(s): Xavier Thomas (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 12, 2019 Category: Hematology Source Type: research

Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement
Publication date: Available online 7 December 2019Source: The Lancet HaematologyAuthor(s): Kris M Mahadeo, Rajinder Bajwa, Hisham Abdel-Azim, Leslie E Lehmann, Christine Duncan, Nicole Zantek, Jennifer Vittorio, Joseph Angelo, Jennifer McArthur, Keri Schadler, Sherwin Chan, Priti Tewari, Sajad Khazal, Jeffery J Auletta, Sung Won Choi, Basirat Shoberu, Krzysztof Kalwak, Avis Harden, Partow Kebriaei, Jun-ichi AbeSummarySinusoidal obstructive syndrome, also known as hepatic veno-occlusive disease, is a potentially life-threatening complication that occurs in children undergoing haemopoietic stem-cell transplantation (HSCT). D...
Source: The Lancet Haematology - December 8, 2019 Category: Hematology Source Type: research

Proliferation and differentiation
Publication date: Available online 7 December 2019Source: The Lancet HaematologyAuthor(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 8, 2019 Category: Hematology Source Type: research

Gita Thanarajasingam: making treatment more tolerable
Publication date: Available online 5 December 2019Source: The Lancet HaematologyAuthor(s): Rachael Davies (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 6, 2019 Category: Hematology Source Type: research

Eligibility criteria in haematological cancer clinical trials—what's needed?
Publication date: Available online 5 December 2019Source: The Lancet HaematologyAuthor(s): Mattia Calissano, Maria Beatrice Panico, Daniel J O'Connor (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 6, 2019 Category: Hematology Source Type: research

Should high-risk smouldering multiple myeloma be treated?
Publication date: Available online 4 December 2019Source: The Lancet HaematologyAuthor(s): Shambavi Richard, Sundar Jagannath, Mario Boccadoro, Roberto Mina (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 5, 2019 Category: Hematology Source Type: research

Diversity and Inclusion in Haematology
Publication date: Available online 3 December 2019Source: The Lancet HaematologyAuthor(s): Ariela Marshall (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 5, 2019 Category: Hematology Source Type: research

Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states
Publication date: Available online 3 December 2019Source: The Lancet HaematologyAuthor(s): Lukasz P Gondek, Amy E DeZernSummaryDiagnosing, surveilling, and understanding the biological consequences of clonal haematopoiesis poses a clinical challenge for both patients and clinicians. The relationship between peripheral blood cytopenias and myeloid neoplasms—such as myelodysplastic syndrome—is an area of active research, and understanding of clonal haematopoiesis has developed markedly on the basis of findings concerning somatic mutations in genes known to be associated with myelodysplastic syndrome. These findin...
Source: The Lancet Haematology - December 5, 2019 Category: Hematology Source Type: research

Using it wisely: catheter-directed thrombolysis for deep vein thrombosis
Publication date: Available online 27 November 2019Source: The Lancet HaematologyAuthor(s): Suresh Vedantham (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 28, 2019 Category: Hematology Source Type: research

Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial
This study is complete and is registered at ClinicalTrials.gov, NCT00970619.FindingsBetween May 28, 2010, and Sept 18, 2017, 184 patients were randomly assigned to either additional ultrasound-accelerated catheter-directed thrombolysis (n=91) or standard treatment alone (n=93). Exclusion because of screening failure or early withdrawal of informed consent resulted in 77 patients in the intervention group and 75 in the standard treatment group starting allocated treatment. Median follow-up was 12·0 months (IQR 6·0–12·0). 12-month post-thrombotic syndrome occurred in 22 (29%) patients allocated to ...
Source: The Lancet Haematology - November 28, 2019 Category: Hematology Source Type: research

Essential medicines: a balancing act
Publication date: December 2019Source: The Lancet Haematology, Volume 6, Issue 12Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 27, 2019 Category: Hematology Source Type: research

Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility study
Publication date: Available online 6 November 2019Source: The Lancet HaematologyAuthor(s): Sandra Cohen, Jean Roy, Silvy Lachance, Jean-Sébastien Delisle, Anne Marinier, Lambert Busque, Denis-Claude Roy, Frédéric Barabé, Imran Ahmad, Nadia Bambace, Léa Bernard, Thomas Kiss, Philippe Bouchard, Pierre Caudrelier, Sévérine Landais, Fannie Larochelle, Jalila Chagraoui, Bernhard Lehnertz, Sophie Corneau, Elisa TomelliniSummaryBackgroundBenefits of cord blood transplantation include low rates of relapse and chronic graft-versus-host disease (GVHD). However, the use of cord blood i...
Source: The Lancet Haematology - November 7, 2019 Category: Hematology Source Type: research

A resurgence of cord blood transplantation?
Publication date: Available online 6 November 2019Source: The Lancet HaematologyAuthor(s): Mary Eapen (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 7, 2019 Category: Hematology Source Type: research

Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
Publication date: Available online 5 November 2019Source: The Lancet HaematologyAuthor(s): Christoph Male, Anthonie W A Lensing, Joseph S Palumbo, Riten Kumar, Ildar Nurmeev, Kerry Hege, Damien Bonnet, Philip Connor, Hélène L Hooimeijer, Marcela Torres, Anthony K C Chan, Gili Kenet, Susanne Holzhauer, Amparo Santamaría, Pascal Amedro, Elizabeth Chalmers, Paolo Simioni, Rukhmi V Bhat, Donald L Yee, Olga LvovaSummaryBackgroundTreatment of venous thromboembolism in children is based on data obtained in adults with little direct documentation of its efficacy and safety in children. The aim of our study was...
Source: The Lancet Haematology - November 5, 2019 Category: Hematology Source Type: research

Can paediatricians move directly to direct oral anticoagulants?
Publication date: Available online 5 November 2019Source: The Lancet HaematologyAuthor(s): Sarah H O'Brien (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 5, 2019 Category: Hematology Source Type: research

International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study
Publication date: Available online 31 October 2019Source: The Lancet HaematologyAuthor(s): Wolfgang R Sperr, Michael Kundi, Ivan Alvarez-Twose, Bjorn van Anrooij, Joanna N G Oude Elberink, Aleksandra Gorska, Marek Niedoszytko, Karoline V Gleixner, Emir Hadzijusufovic, Roberta Zanotti, Patrizia Bonadonna, Massimiliano Bonifacio, Cecelia Perkins, Anja Illerhaus, Chiara Elena, Serena Merante, Khalid Shoumariyeh, Nikolas von Bubnoff, Roberta Parente, Mohamad JawharSummaryBackgroundThe WHO classification separates mastocytosis into distinct variants, but prognostication remains a clinical challenge. The aim of this study was to...
Source: The Lancet Haematology - November 1, 2019 Category: Hematology Source Type: research

A useful add-on international prognostic score for mastocytosis?
Publication date: Available online 31 October 2019Source: The Lancet HaematologyAuthor(s): Stéphane Barete (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 1, 2019 Category: Hematology Source Type: research

Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study
Publication date: Available online 25 October 2019Source: The Lancet HaematologyAuthor(s): Effie W Petersdorf, Mary Carrington, Colm O'hUigin, Mats Bengtsson, Dianne De Santis, Valerie Dubois, Ted Gooley, Mary Horowitz, Katharine Hsu, J Alejandro Madrigal, Martin J Maiers, Mari Malkki, Caroline McKallor, Yasuo Morishima, Machteld Oudshoorn, Stephen R Spellman, Jean Villard, Phil Stevenson, Effie W Petersdorf, Mary CarringtonSummaryBackgroundThe success of unrelated haemopoietic cell transplantation (HCT) is limited by graft-versus-host disease (GVHD), which is the main post-transplantation challenge when HLA-matched donors...
Source: The Lancet Haematology - October 26, 2019 Category: Hematology Source Type: research

GVHD risk assessment beyond current HLA evaluation
Publication date: Available online 25 October 2019Source: The Lancet HaematologyAuthor(s): Sophie Paczesny (Source: The Lancet Haematology)
Source: The Lancet Haematology - October 26, 2019 Category: Hematology Source Type: research

Changing the face of clinical trials
Publication date: November 2019Source: The Lancet Haematology, Volume 6, Issue 11Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - October 23, 2019 Category: Hematology Source Type: research

European Congress on Thrombosis and Haemostasis 2019
Publication date: November 2019Source: The Lancet Haematology, Volume 6, Issue 11Author(s): Yaiza del Pozo Martín (Source: The Lancet Haematology)
Source: The Lancet Haematology - October 23, 2019 Category: Hematology Source Type: research

Blood products: unmet needs for essential medicines
Publication date: Available online 17 October 2019Source: The Lancet HaematologyAuthor(s): Thierry Burnouf (Source: The Lancet Haematology)
Source: The Lancet Haematology - October 18, 2019 Category: Hematology Source Type: research

The global need and availability of blood products: a modelling study
Publication date: Available online 17 October 2019Source: The Lancet HaematologyAuthor(s): Nicholas Roberts, Spencer James, Meghan Delaney, Christina FitzmauriceSummaryBackgroundBlood transfusions are an important resource of every health-care system, with often limited supply in low-income and middle-income countries; however, the degree of unmet need for blood transfusions is often unknown. We therefore aimed to estimate the blood transfusion need and supply at national level to determine gaps in transfusion services globally.MethodsWe did a modelling study involving 195 countries and territories. We used blood component...
Source: The Lancet Haematology - October 18, 2019 Category: Hematology Source Type: research

Frontline therapy in multiple myeloma: fast start for a long game
Publication date: Available online 14 October 2019Source: The Lancet HaematologyAuthor(s): Francesca Patriarca (Source: The Lancet Haematology)
Source: The Lancet Haematology - October 15, 2019 Category: Hematology Source Type: research

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
This study is registered with the ISRCTN registry, number ISRCTN49407852, and clinicaltrialsregister.eu, number 2009–010956–93, and has completed recruitment.FindingsBetween Nov 15, 2010, and July 28, 2016, 583 patients were enrolled to the intensification randomisation, representing 48% of the 1217 patients who achieved partial or minimal response after initial induction therapy. 289 patients were assigned to CVD treatment and 294 patients to no treatment. After a median follow-up of 29·7 months (IQR 17·0–43·5), median progression-free survival was 30 months (95% CI 25–36) with...
Source: The Lancet Haematology - October 15, 2019 Category: Hematology Source Type: research